The nuclear export protein XPO1—from biology to targeted therapy

AS Azmi, MH Uddin, RM Mohammad - Nature reviews Clinical oncology, 2021 - nature.com
Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

Nucleo-cytoplasmic transport as a therapeutic target of cancer

GL Gravina, W Senapedis, D McCauley… - Journal of hematology & …, 2014 - Springer
Shuttling of specific proteins out of the nucleus is essential for the regulation of the cell cycle
and proliferation of both normal and malignant tissues. Dysregulation of this fundamental …

[HTML][HTML] Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

KB Emdal, N Palacio-Escat, C Wigerup, A Eguchi… - Cell Reports, 2022 - cell.com
Acute myeloid leukemia (AML) is a heterogeneous disease with variable patient responses
to therapy. Selinexor, an inhibitor of nuclear export, has shown promising clinical activity for …

[HTML][HTML] Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma

UH Gandhi, W Senapedis, E Baloglu, TJ Unger… - … Myeloma and Leukemia, 2018 - Elsevier
Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse
is common. Current therapeutic strategies include combination and sequential treatments …

Targeting nuclear import and export in hematological malignancies

B Nachmias, AD Schimmer - Leukemia, 2020 - nature.com
The transport of proteins across the nuclear membrane is a highly regulated process,
essential for the cell function. This transport is actively mediated by members of the …

Atomic basis of CRM1-cargo recognition, release and inhibition

HYJ Fung, YM Chook - Seminars in cancer biology, 2014 - Elsevier
CRM1 or XPO1 is the major nuclear export receptor in the cell, which controls the nuclear-
cytoplasmic localization of many proteins and RNAs. CRM1 is also a promising cancer drug …

[HTML][HTML] Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to …

T Kashyap, C Argueta, A Aboukameel, TJ Unger… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The nuclear export protein, exportin-1 (XPO1/CRM1), is overexpressed in many cancers and
correlates with poor prognosis. Selinexor, a first-in-class Selective Inhibitor of Nuclear Export …

The nuclear proteome of a vertebrate

M Wühr, T Güttler, L Peshkin, GC McAlister, M Sonnett… - Current biology, 2015 - cell.com
The composition of the nucleoplasm determines the behavior of key processes such as
transcription, yet there is still no reliable and quantitative resource of nuclear proteins …

Structure-based virtual screening approach for discovery of covalently bound ligands

D Toledo Warshaviak, G Golan… - Journal of chemical …, 2014 - ACS Publications
We present a fast and effective covalent docking approach suitable for large-scale virtual
screening (VS). We applied this method to four targets (HCV NS3 protease, Cathepsin K …

[HTML][HTML] Emerging roles of miR-145 in gastrointestinal cancers: A new paradigm

M Roshani, D Molavizadeh, S Sadeghi, A Jafari… - Biomedicine & …, 2023 - Elsevier
Gastrointestinal (GI) carcinomas are a group of cancers affecting the GI tract and digestive
organs, such as the gastric, liver, bile ducts, pancreas, small intestine, esophagus, colon …